Biotech Values

[DewDiligence]

Tecentriq/Avastin shows superior OS—(HR=0.58)—and superior PFS—(HR-0.59)—compared to Nexavar monotherapy in first-line HCC:

https://www.businesswire.com/news/home/20191122005376/en

Checkpoint inhibitors alone have previously shown only modest (non-statsig) efficacy in HCC—e.g. #msg-149555601, #msg-146956118.

It’s somewhat bizarre to see Avastin playing a role in a new indication after all these years.